WT1 encodes a transcription factor involved in kidney development and tumorigenesis. Using representational difference analysis, we identified a new set of WT1 targets, including a homologue of the Drosophila receptor tyrosine kinase regulator, sprouty. Sprouty1 was upregulated in cell lines expressing wild-type but not mutant WT1. WT1 bound to the endogenous sprouty1 promoter in vivo and directly regulated Spry1 through an EGR1 binding site.
Introduction
The development of the mammalian metanephric kidney is a model for the study of cellular and molecular mechanisms of organogenesis (1) . Wilms tumor, a pediatric kidney malignancy, is characterized by a triphasic histopathology (blastemal, stromal, epithelial) signifying an abnormal differentiation program. In accordance with this notion, the Wilms Tumor suppressor gene 1 (WT1), inactivated in a subset of Wilms tumors, plays an essential role in normal development of the kidney and the genitourinary system (2) (3) (4) . Targeted disruption of WT1 in mice leads to a complete agenesis of the kidneys and gonads (5) . The specific temporal and spatial pattern of WT1 expression suggests multiple roles for WT1 during nephrogenesis. In particular, WT1 expression peaks during the mesenchymal-to-epithelial transition (MET), suggesting an instructive role in the formation of the renal glomerulus. In the mature kidney, WT1 expression becomes restricted to the podocytes, perhaps being involved in maintaining a differentiated phenotype.
The WT1 gene encodes a C 2 -H 2 zinc finger transcription factor that binds to both GC-rich and TC repeat elements. Alternative splicing at two sites yields four major isoforms, each containing or lacking 17 amino acids between the transactivation domain and the zinc finger region and/or a 3 amino acid insertion (KTS) between the third and fourth zinc fingers. The KTS
Materials and methods

Cell culture, transfection and infection
NIH3T3, maintained in DMEM with 10% calf serum, were transiently transfected by Lipofectamine Plus (Life Technologies) using 0.1mg of the various mouse Spry1 luciferase reporters, 0.005mg of a thymidine kinase Renilla reporter as internal control and 1mg of an empty vector (RSV) or WT1 expression vectors (RSV-WT1A and WT1C, (27) ). Cells were harvested 48 h later and assayed for luciferase activity using a Dual reporter assay (Promega) and for protein expression by immunoblotting. Tet-Off Saos-2 osteosarcoma cells (gift of Dr. D. Haber, Massachusetts General Hospital) were transfected with a pTRE vector (Clontech) expressing wild type WT1A, WT1A112 or WT1A129 followed by selection in 0.2mg/ml puromycin.
Retroviral infection (28) and the WT1A-expressing NIH3T3 (9) were described. mIMCD-3 (29) were maintained in DMEM/Ham's F-12 medium with 10% fetal calf serum.
RDA
Double-stranded cDNAs were synthesized with 5mg of polyA + RNA from NIH3T3 and WR16 cells and RDA was performed (10) . To identify genes activated by WT1, 3 rounds of RDA subtracting the 3T3 representation from the WR16 representation were performed (WR16 -3T3).
To identify repressed genes, the reciprocal subtractions were done in parallel (3T3 -WR16). The differential products were sub-cloned into pBluescript SK-(Stratagene). To confirm that the cDNA fragments were present in different amounts, each was 32 P labeled and used as a probe to hybridize blots of NIH3T3 or WR16 representations. This step eliminated false positives (30%) before sequencing.
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Cloning of the Spry1 cDNA
The nucleotide (nt) positions for murine Spry1 (mSpry1) are listed under AF176903. From RDA, a cDNA corresponding to nt 1079-1693 of mSpry1 was isolated and used to identify an EST (Genebank AA591484, clone ID 907842) containing nt 962-2489 of mSpry1. The 5' end of mSpry1 was obtained by RACE PCR (Marathon cDNA Amplification Kit, Clontech). Briefly, 1mg of polyA + RNA from podocytes was reverse transcribed using a mSpry1 primer (nt 1016-1040). After 2 nd strand synthesis and ligation to the anchor oligonucleotide, PCR was performed using a primer corresponding to the anchor and a mSpry1 primer (nt 988-1007). The resulting products were sub-cloned and sequenced. One RACE product (nt 402-1007 of mSpry1) was ligated to the above EST clone at a common StuI site. The mSpry1 CDS (nt 481-1469) was amplified by PCR from the full-length cDNA and cloned in frame with the sequence of the Flag tag in a modified pcDNA 3-1 (+) vector (30) .
Spry1 genomic cloning and reporter plamids
A bacterial artificial chromosome library was screened (Incyte Genomics, St Louis, MO) using primers from the mSpry1 cDNA (nt 1171-1191 and nt 1405-1422) and confirmed by Southern blot with a probe derived from the 5' end of the mSpry1 cDNA. A 9 kb EcoRI fragment encompassing the mSpry1 coding exon and 5' and 3' sequences was subcloned into pBluescript SK+ and sequenced (MWG Biotech Inc). The start site of transcription was mapped by primer extension. A 1.1 kb SacI fragment containing the proximal promoter was ligated into pGL2basic (Promega). A series of 5' truncations were created by PCR using forward primers located at 3') and -137 (5'-GGTACCTGCTCCGGGTTTTTG-3') and reverse primer located at +20 (5'-AGATCTGAGCTCTGGCTGCGG-3') and sub-cloned with KpnI/BglII into pGL2basic.
M u t a t i o n s o f M I N 1 ( C CG G G G G CG to CCT T T T T CG-87), MIN2A
(GCGTGGAGGTGGAGGTG to GCTTTGAGGTGTAGGTA) and MIN2B (GCGCGACG to GCTTTTACG) binding sites within the SPRY137-luc reporter were created by site-directed mutagenesis (QuikChange, Statagene).
EMSA
Double-stranded oligonucleotide probes encompassing 8 putative WT1 binding sites within the mSpry1 promoter were end-labeled with a-
32
P dCTP and Klenow. The oligonucleotide probes were:
In vitro coupled transcription/translations (Promega) were performed with pSP64-WT1A, pSP64-WT1C and pSP64 control vector. 8µl of lysate were preincubated for 15 min at RT along with 1mg poly (dI-dC), 5mg BSA and binding buffer (20mM HEPES (pH 7.5), 70mM KCl, 5mM
MgCl 2 , 0.1% NP-40, 12% glycerol, 0.5mM DTT, 100µM ZnCl 2 ) in a volume of 20µl followed 9 by addition of radiolabeled probe (50,000 cpm) for another 15 min. Protein/DNA complexes were resolved on a 5% non-denaturing polyacrylamide gel in 0.5X TBE at 300 V for 1.5 h. For competition experiments, 0.4mg of WT1 antibody (C-19, Santa Cruz) or rabbit IgG (Zymed) or a 1000x excess of cold MIN1, MutMin1 or mut NF-kB (GGCATAGGTCC) oligonucleotides were added during pre-incubation.
Chromatin immunoprecipitation
Proteins were crosslinked to DNA by adding formaldehyde directly to the cell media to a concentration of 1% for 10 min at 37°C. Crosslinking was stopped by addition of glycine to 
Immunoblotting
A rabbit polyclonal serum was generated against a peptide corresponding to aa 81-93 of mSpry1
(NP_036026) and affinity purified (Covance, Denver, PA). The GAPDH antibody (MAB374) was purchased from Chemicon and the WT1 antibody (C19) used in western blot was from Santa
Cruz. Total cell lysates were analyzed by SDS-PAGE and immunoblotted as described (23) .
Kidney explant ISH and immunostaining, whole-embryo ISH
Metanephric rudiments were dissected from E11.5 embryos into MEM (GIBCO) medium with 10% FBS, 20mM glutamine and penicillin/streptomycin and grown for 1-4 days on 1 mm polycarbonate Transwell TM filters (Costar) at 5% CO 2 , 37°C. After fixation (4% PFA in PBS overnight), all ISH were performed as described with hybridizations and washes carried out at 65°C (32) . Probes corresponding to nt 1345-1652 of mSpry1 and nt 529-799 of mSpry2
(AF176905) were synthesized as described (33), but fragmented by alkaline hydrolysis. Wholeembryo ISH was performed as described (34) . Antibodies for immunofluorescence included rabbit anti-Spry1 (1/500), mouse anti-WT1 (H2, DAKO, 1/100), Cy5-conjugated goat anti-rabbit
IgG and Biodipy-conjugated anti-mouse IgG.
Morpholino oligonucleotide assays
E12 fetal kidney pairs were dissected and grown as described (35) . Morpholino oligonucleotides antisense to Spry1 (Spry1: GGAGTGATCTCCAGTTCCAGCAGTC) and control oligonucleotides (Ct, invert of the antisense CTGACGACCTTGACCTCTAGTGAGG or random CCTCTTACCTCAGTTACAATTTATA) were purchased from Gene Tools (Philomath, OR) and added to the medium (20mM) daily. Due to developmental variability within litters, right and left kidneys from the same embryo were compared to each other in the following ways:
i) medium versus medium plus Ct morpholinos; ii) medium plus Ct morpholinos versus medium plus Spry1 morpholinos; iii) medium versus medium plus Spry1 morpholinos. After 3-5 days,
Results
Activation of Spry1 expression by constitutive or induced WT1 expression
To identify WT1 target genes, we applied RDA to mRNAs extracted from parental NIH3T3 cells and WT1A-overexpressing NIH3T3 cells (WR16, (9)). A total of 11 differentially expressed genes were isolated 1 , none of which were previously identified as WT1 targets. Notable among these genes was a murine homologue of Drosophila Spry (11) . Drosophila Spry, an antagonist of tracheal branching morphogenesis, was genetically shown to inhibit Ras signaling (11, 12) . Given the importance of branching morphogenesis in kidney development (37) missense mutants (F112Y and P129L) that yield proteins defective for transcriptional activation (27) failed to up-regulate Spry1 ( Figure 1D ). Thus, in three different systems, endogenous Spry1 expression was activated by WT1.
WT1 directly activates the Spry1 promoter
To determine whether WT1 directly activates Spry1 expression, regulatory sequences for this gene were cloned and sequenced (accession #AY260058) and the start site of transcription was along with the WT1 protein.
Mutation of the MIN1 site in the context of the SPRY137 luciferase reporter reduced WT1-mediated transactivation by 50% ( Figure 3E ). Two different mutations of MIN2, which weakly bound WT1A in vitro, had no effect on WT1 transactivation, either alone or in combination with the MIN1 mutation ( Figure 3E ). Taken together the data indicate that WT1
activates transcription through direct binding to an EGR1 site within the Spry1 promoter. The residual transactivation in the presence of a mutated MIN1 site might be due to the adjacent CAAT box sequence, which we previously showed to promote WT1 transactivation (28) . This explanation is consistent with the ability of WT1C to transactivate in the absence of DNA binding.
Expression of Spry1 during kidney development
To determine the relationship between Spry1 and WT1, the expression pattern of Spry1 was examined. In adult mouse tissues, Spry1 transcripts were detected by Northern blot in heart, lung and, most importantly, kidney ( Figure 4A ). Next, we compared the expression of WT1 and Spry1 during embryonic development. In situ hybridization (ISH) of whole-embryo sections detected To further correlate Spry1 and WT1 expression, murine kidney rudiments from E11.5 embryos were cultured for four days and analyzed by immunofluorescence. Spry1 was detected in both the condensing mesenchyme and the ureteric tree ( Figure 5, a) . Moreover, doublelabeling experiments using a monoclonal anti-WT1 antibody demonstrated concordant expression of WT1 and Spry1 proteins in the condensing metanephric mesenchyme ( Figure 5, b and c). Since WT1 is a nuclear protein and Spry 1 is a cytoplasmic protein (19) , the staining did not exactly overlay. Nevertheless, these data suggest that Spry1 is involved in the development of the embryonic kidney and are consistent with the notion that WT1 can control Spry1 expression.
To map the expression of Spry1 during kidney development, explants from E11.5 embryos were cultured for one to four days and subjected to ISH. Spry1 exhibited a dynamic pattern during renal development ( Figure 6 A-E). As the ureteric bud invaded the metanephric blastema, strong Spry1 expression was observed in the metanephric mesenchyme condensing around the tips of the ureteric buds ( Figure 6A , cm and arrow). The ureteric tree showed weaker expression of Spry1 mRNA ( Figure 6B, arrow) . As the explant matured, Spry1 was also expressed in the comma and S-shaped bodies ( Figure 6C , E, cb), as well as in the ureteric tree ( Figure 6C , D, arrows). WT1, as reported (41, 42) , was expressed in the differentiating blastema, but not in the ureteric tree ( Figure 6F ). Therefore, WT1 and Spry1 expression was coincident in both the uninduced and the condensing mesenchyme. ISH performed on paraffin sections of embryonic kidneys gave similar results (data not shown).
Murine Spry1 belongs to a family of genes often co-expressed during embryogenesis (13, 14, 26, 43) . As a control for the specificity of Spry1 as a WT1 target gene in the kidney, Spry2 expression was also examined ( Figure 6G, H) . Spry2 was first expressed in the ureteric bud as it invaded the metanephric mesenchyme. It was not restricted to the ureteric epithelium, but extended into the adjacent mesenchyme ( Figure 6G , *). In more mature explants, Spry2 decreased in the ureteric epithelium and was expressed in renal stromal cells surrounding the mesenchyme undergoing epithelial transition ( Figure 6H , "). In contrast to Spry1, Spry2 was neither expressed in the condensing metanephric blastema, nor in the comma and S-shaped bodies. Thus, expression of Spry1 suggests a specific role for this particular gene during metanephric development.
Disruption of Spry1 expression in embryonic kidney explants
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In order to gain insight into the possible role of Spry1 during kidney development, we used antisense morpholino oligonucleotides (morpholinos), reported to be more specific than traditional oligonucleotides (44) , to examine the consequences of disruption of Spry1 expression in the developing metanephric kidney. Paired murine kidney rudiments were isolated from E12 embryos and grown in culture for three days in the absence or presence of morpholinos before fixation and staining. Explants grown in the presence of Spry1 antisense morpholinos were normal in size but exhibited a 50% reduction in the number of developing and mature glomeruli (visualized by peanut lectin staining of visceral podocytes (45) , Figure 7A , a-b, and Figure 7B ).
This effect was specific, as explants treated with control morpholinos (invert of the antisense or random) developed normally. The number of ureteric branches and tips (visualized by Dolichos bifloris lectin staining, (45) ) that formed in the kidney explants treated with Spry1 morpholinos (and exhibiting less glomeruli) was not significantly different from control explants (data not shown). However, histochemical sections revealed that ureteric trees from antisense-treated kidneys tended to be less elongated between branch points and had wider, cystic, tubular lumens ( Figure 7A , c-d).
The explants were further characterized using different markers of renal development.
Pax2, a marker of early metanephric development (46) , was detected in the induced mesenchyme condensing around the ureteric bud of control explants ( Figure 7C, a) . In contrast, expression of the ureteric tree must occur independent of WT1 expression, which is absent in this structure.
Therefore, transcription factors present in both the ureteric tree and the condensing mesenchyme, such as Pax2, might also regulate Spry1 expression (49).
WT1 as a transcriptional activator
The identity of WT1 targets and the transcriptional function of WT1 have been controversial (2). WT1 was previously thought to inhibit cell proliferation by repression of growth-promoting genes. However, a survey using several cellular models failed to confirm regulation of sixteen genes proposed to be repressed by WT1 (50) . This information suggested that the initial characterization of WT1 as a transcriptional repressor needed to be re-evaluated. Now data from our group and others indicate that WT1 functions by activating growth suppressor genes such as Spry1, p21 or E-cadherin (27, 28, 51) and inducing genes required for the differentiation of the kidney such as podocalyxin (52) . Eight of eleven genes identified in our RDA screen were activated by WT1 and using microarray analysis, Lee et al. (39) only found genes activated by WT1. Previously, our group demonstrated that three Wilms tumor-derived point mutations that abrogate the growth inhibition by WT1 were competent for transcriptional repression but defective for transcriptional activation of reporter genes (27) . These same point mutants failed to up-regulate the endogenous Spry1 gene. Thus, the transcriptional activation properties of WT1, once controversial, appear now to be critical for its biological role.
Analysis of the Spry1 promoter revealed 8 potential WT1 binding sites; of these, only the 5'EGR1 site was a complete match to known WT1 sites and only this site strongly bound WT1.
Consistent with prior reports, WT1 could also transactivate without direct DNA binding (28) .
For example, the E-cadherin promoter, like that of Spry1, contains a CAAT box immediately upstream of the EGR1 site (28) . This CAAT box supported minimal WT1 transactivation in the presence of a mutation in the EGR1 site even though WT1 did not bind directly to this element.
In the amphiregulin promoter, the CRE element adjacent to the WT1-binding site was responsive to WT1 while not being directly bound by WT1 (39). This was possibly due to protein-protein interactions between WT1 and CBP, a co-activator of CRE-binding factors . Finally, WT1 associated and synergized with the steroidogenic factor 1 (SF-1) to activate MIS expression (53).
SF-1, but not WT1, bound to the MIS promoter. The identification of additional WT1 co-factors, potentially those that bind to the CAAT box, will help explain the full range of WT1 activity.
Possible roles for Spry1 during kidney development
Induction of the metanephric blastema by the invading ureteric bud is a key step in kidney development. The ureteric bud grows out from the Wolffian duct and into the metanephric mesenchyme, where it branches and induces nephron formation (54) . Mesenchymal cells of the blastema condense around the ureteric bud, undergo a MET and form the nephric epithelium. This tightly controlled process involves changes in cell survival, proliferation and differentiation. WT1 is expressed in the induced blastemal cells and plays a key role in this process. WT1 null mice lack kidneys (5) and mice which do not express the -KTS isoforms of WT1 (WT1A and WT1B) demonstrate a decrease in the nephrogenic zone and a reduction of the number of glomeruli (55) . Moreover, the MET is disrupted in Wilms tumors with a direct correlation between the level of WT1 expression and the degree of epithelial differentiation (56) .
As expected of a potential WT1 effector, Spry1 was shown to inhibit proliferation of mesenchymal cells (23) . Like WT1, Spry1 is expressed in the condensing mesenchyme and may relay some of the activity of WT1 during nephrogenesis. For instance, treatment of kidney explants with Spry1 morpholinos led to fewer mature glomeruli and a defect in Pax2 expression, suggesting a failure of induction of the metanephric mesenchyme adjacent to the ureteric bud.
Strikingly, mice deficient for the -KTS isoforms of WT1 showed a similar lack of mesenchyme condensation (55). WT1 expression is also required for the proper formation and maintenance of the glomerulus (55, 57) . However, microscopic and immunofluorescence analysis of those glomeruli that did form in the presence of Spry1 morpholinos did not reveal any striking difference in morphology. This could be due to an incomplete suppression of Spry1 expression by the morpholinos. Alternatively, this might indicate that Spry1 modulates the threshold of growth factor signaling that allows epithelial differentiation and glomerulus formation, but is dispensable for the maintenance of the differentiated phenotype. Further analysis will be required to understand the exact role of Spry1 in nephrogenesis but the results presented here suggest an important role for Spry1 in the early stages of the MET in the metanephric blastema and support its identification as a WT1 target gene.
Spry1 also plays a role the development of the ureteric tree. Given that WT1 is not Initial studies did not reveal functional differences between the different Spry members, so it was postulated that the Spry proteins may play redundant roles (14) . However, this does not appear to be true in the kidney. Spry2 was expressed in a distinctly different pattern from Spry1 and WT1 could not induce the expression of Spry2 or Spry4 (data not shown). Hence, the expression pattern of Spry1 in the kidney and its relationship with WT1 are specific.
In conclusion, our results suggest that Spry1 is a bona fide WT1 target gene. Spry1, by regulating RTK-dependent Ras signaling, may contribute to several stages of kidney development. Future studies of gene-targeted animals and organ culture models will further clarify the role of the Spry genes during mammalian kidney development. Spry1 protein is detected in both the condensing mesenchyme and the ureteric tree, whereas WT1 is only present in the differentiating mesenchyme. Since WT1 is a nuclear protein and Spry1 a cytoplasmic protein, the dual signal does not generally appear yellow. 
